Clinical utility may be greatest with careful patient selection, given frailty-associated toxicity and potential endpoint ...
Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...
Erasca (NASDAQ:ERAS) executives outlined the company’s strategy to target RAS-driven cancers and previewed upcoming clinical milestones during a fireside chat hosted by Oppenheimer oncology analyst ...
Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...
ISM6166 was nominated as a PCC as an oral, broad-spectrum pan‑KRAS ON/OFF inhibitor, designed to overcome resistance ...
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over ...
Barclays 28th Annual Global Healthcare Conference March 11, 2026 10:30 AM EDTCompany ParticipantsSanjiv Patel - ...
SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM ...
11d
Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
TD Cowen 46th Annual Health Care Conference March 2, 2026 3:10 PM ESTCompany ParticipantsSanjiv Patel - CEO, President ...
KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results